Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Non-Inferiority Study of DS-5670a vs Comirnaty in Adults
jRCT2031220264Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of DS-5670a in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Sep 2022; status: completed.
02
Drugs
DS-5670a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220264.